Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from OKYO Pharma Limited Sponsored ADR ( (OKYO) ) is now available.
On July 16, 2025, OKYO Pharma announced positive results from its Phase 2 trial of urcosimod for treating neuropathic corneal pain, with 75% of patients showing significant pain reduction. The trial’s success positions OKYO as a leader in addressing this unmet need, with plans to accelerate further clinical development and engage with the FDA for next steps.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.
OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on ophthalmology, specifically developing treatments for neuropathic corneal pain (NCP), a condition with no FDA-approved therapies. The company is pioneering the development of urcosimod, a drug aimed at addressing this unmet medical need.
Average Trading Volume: 163,269
Technical Sentiment Signal: Buy
Current Market Cap: $96.55M
See more data about OKYO stock on TipRanks’ Stock Analysis page.